3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
2
Gynecologic
2
Gastrointestinal
2
Breast
2
Sarcoma
1
Other hematologic neoplasm
1
Head & Neck
1
Genitourinary
1
Dermatologic
1
CNS
1
Conditions
Leukemia, Myeloid, Acute
2
Leukemia
2
Urinary Bladder Neoplasms
1
Stomach Neoplasms
1
Sezary Syndrome
1
Sarcoma
1
Recurrence
1
Prostatic Neoplasms
1
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
1
Pancreatic Neoplasms
1
Ovarian Neoplasms
1
Neoplasms
1
Neoplasm Metastasis
1
Myelodysplastic Syndromes
1
Mycosis Fungoides
1
Melanoma
1
Lymphoma, T-Cell, Peripheral
1
Lymphoma, T-Cell, Cutaneous
1
Lung Neoplasms
1
Liver Neoplasms
1
Leukemia-Lymphoma, Adult T-Cell
1
Leukemia, Prolymphocytic, T-Cell
1
Kidney Neoplasms
1
High-risk Leukemias
1
Glioblastoma
1
Esophageal Neoplasms
1
Disease
1
Colorectal Neoplasms
1
Carcinoma, Bronchogenic
1
Bronchiolitis Obliterans Syndrome
1
Interventions
Gemcitabine
3
sargramostim
2
pertuzumab
2
binimetinib
2
Trastuzumab
2
Specimen Handling
2
Polymerase Chain Reaction
2
Paclitaxel
2
Nicotine
2
Magnetic Resonance Spectroscopy
2
Doxorubicin
2
Counseling
2
Bupropion
2
Azacitidine
2
vandetanib
1
ulixertinib
1
trastuzumab biosimilar HLX02
1
trametinib
1
temsirolimus
1
tanespimycin
1
sapanisertib
1
romidepsin
1
relatlimab
1
pembrolizumab
1
palbociclib
1
osimertinib
1
omipalisib
1
motexafin gadolinium
1
motesanib diphosphate
1
liposomal doxorubicin
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Lung Neoplasms
×
Interleukin-15
×
Other hematologic neoplasm
×
Clear all
NCT07410676
2026-02-18
EBNK-ST-001
Essen Biotech
Phase 1/2
Recruiting
83 enrolled